Thomas Widmann

Thomas Widmann has been appointed to the board of Cancer Genetics. He founded Actelion Pharmaceuticals and is a venture partner at Wellington Partners. Wildmann is also the founder of Hesperion, Widmann Associates, and Auraglobe. Before that he spent nine years at Hoffmann-La Roche where he led the international cardiovascular development department.